| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12016-007-0043-6 |
| P698 | PubMed publication ID | 18163226 |
| P2093 | author name string | Chih-Jung Hsu | |
| Li-Fang Wang | |||
| P2860 | cites work | Hay fever, hygiene, and household size | Q24674856 |
| Probiotics in the management of atopic eczema | Q28143271 | ||
| Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial | Q28211907 | ||
| Increased urinary leukotriene E4 excretion in patients with atopic dermatitis | Q31892451 | ||
| The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group | Q33863853 | ||
| Safety of sublingual-swallow immunotherapy in children and adults | Q33870761 | ||
| Probiotics: a novel approach in the management of food allergy | Q34738168 | ||
| Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases | Q35015845 | ||
| Noninjection routes for immunotherapy | Q35087289 | ||
| Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study | Q35107655 | ||
| Pathophysiology of atopic dermatitis | Q35111390 | ||
| The treatment of atopic dermatitis with systemic immunosuppressive agents | Q35143066 | ||
| Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. | Q35781569 | ||
| Immunotherapy: 1999-2004. | Q35811871 | ||
| The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues | Q35835017 | ||
| Regulatory T cells and mechanisms of immune system control | Q35852343 | ||
| T-cell trafficking in asthma: lipid mediators grease the way. | Q35877210 | ||
| The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis | Q35956558 | ||
| Probiotics: a complementary approach in the treatment and prevention of pediatric atopic disease | Q36069960 | ||
| Allergy and asthma | Q36114235 | ||
| A pilot study examining the role of zileuton in atopic dermatitis | Q41711836 | ||
| The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis | Q43517090 | ||
| Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil | Q43548644 | ||
| A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. | Q43612221 | ||
| Mycophenolate mofetil is effective in the treatment of atopic dermatitis | Q43674371 | ||
| Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study | Q43688380 | ||
| A comparison of oral and topical corticosteroids in patients with bullous pemphigoid | Q43872841 | ||
| Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients | Q44122718 | ||
| Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults | Q44165666 | ||
| Acute and maintenance treatment of atopic dermatitis in children – two comparative studies with fluticasone propionate (0.05%) cream | Q44604970 | ||
| Variation of the skin end-point in patients treated with sublingual specific immunotherapy | Q44667335 | ||
| Leukotriene receptor antagonists are ineffective for severe atopic dermatitis | Q44779597 | ||
| Leflunomide as a novel treatment option in severe atopic dermatitis | Q44950244 | ||
| Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. | Q46201647 | ||
| Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis | Q46493414 | ||
| Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy | Q47229738 | ||
| Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. | Q51686636 | ||
| Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. | Q52035512 | ||
| Treatment of asthma with drugs modifying the leukotriene pathway. | Q53474242 | ||
| Sublingual immunotherapy. | Q54105175 | ||
| Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. | Q55036595 | ||
| Effect of probiotic Lactobacillus strains in children with atopic dermatitis | Q60291329 | ||
| Treatment of atopic dermatitis with mycophenolate mofetil | Q73309437 | ||
| Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG | Q73310015 | ||
| Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing | Q73375788 | ||
| Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients | Q73770478 | ||
| Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate | Q73968317 | ||
| Treatment of atopic eczema with oral mycophenolate mofetil | Q74198740 | ||
| Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study | Q74566144 | ||
| The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis | Q74816099 | ||
| The intestinal microflora in allergic Estonian and Swedish 2-year-old children | Q77321890 | ||
| Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease | Q77369273 | ||
| Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil | Q78032221 | ||
| Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial | Q81432992 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 199-203 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | Emerging treatment of atopic dermatitis | |
| P478 | volume | 33 |
| Q38469822 | Anti-inflammatory, antinociceptive and anti-angiogenic activities of a phospholipid mixture purified from porcine lung tissues |
| Q99578813 | Antibacterial and Toxicity Evaluation of Eastern Medicine Formulation Eczegone for the Management of Eczema |
| Q92591918 | Childhood atopic dermatitis: current developments, treatment approaches, and future expectations |
| Q37448424 | Evaluation of the efficacy and safety of a Chinese herbal formula (RCM-106) for atopic dermatitis: study protocol for a randomised, double-blind, placebo-controlled trial in children. |
| Q50221638 | Sea Buckthorn (Hippophaë rhamnoides L.) Oil Improves Atopic Dermatitis-Like Skin Lesions via Inhibition of NF-κB and STAT1 Activation |
| Q43206262 | Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients |
| Q37411125 | Systemic therapy of atopic dermatitis in children. |
| Q42217684 | The role of airborne proteins in atopic dermatitis. |
Search more.